Macitentan Drug Asset Due Diligence Report 2026

This Macitentan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Macitentan can convert its Small molecule drug profile and ETA x ETB biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Macitentan (query alias: macitentan)
Modality / target	Small molecule drug; ETA x ETB; ETA antagonists, ETB antagonists
Highest global status	Approved
Originator	Actelion Pharmaceuticals Ltd.
Active developers	Janssen Research & Development LLC, Accord Healthcare, Actelion Pharmaceuticals Ltd.

The MCP disease footprint includes Familial Primary Pulmonary Hypertension, Idiopathic pulmonary arterial hypertension, Pulmonary arterial hypertension associated with congenital heart disease. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07392281	Early Phase 1	Recruiting	40	Changes in coronary microcirculation function parameters assessed by CFR from baseline to week 4
CTR20250942	Not Applicable	已完成	56	Not disclosed
CTR20261777	Not Applicable	进行中（招募完成）	28	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

MACITENTAN FOR SYSTEMIC SCLEROSIS-RELATED DIGITAL VASCULOPATHY: EFFICACY AND SAFETY FROM ON-LABEL AND OFF-LABEL REAL-LIFE COHORTS

Not Applicable; n=62; evaluation: Positive. Reported fields: AE(discontinuation) = Macitentan was discontinued in three patients due to headache, nausea, and flushing - symptoms previously experienced with bosentan - while no cases of elevated transaminases were observed. ; AE(discontinuation) = Macitentan was discontinued in three patients due to headache, nausea, and flushing - symptoms previously experienced with bosentan - while no cases of elevated transaminases were observed.

Macitentan in Pediatric Pulmonary Arterial Hypertension (TOMORROW): A Randomized Clinical Trial

Phase 3; n=148; evaluation: Positive. Reported fields: NT-proBNP(12-week) = 101.0 % ; NT-proBNP(12-week) = 72.0 %

Long-Term Treatment with Single-Tablet Combination of Macitentan and Tadalafil in Pulmonary Arterial Hypertension: Results from A DUE and Its Open-Label Period

Phase 3; n=185; evaluation: Positive. Reported fields: 6MWD(Mean (SD) change from M/T FDC initiation to OL Week 120) = 60.5 m

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Macitentan addresses Familial Primary Pulmonary Hypertension, Idiopathic pulmonary arterial hypertension, Pulmonary arterial hypertension associated with congenital heart disease. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: ETA x ETB records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
No matched asset transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combination of macitentan and tadalafil for the treatment of pulmonary arterial hypertension”. The milestone feed surfaced a patent-application signal described as “The tablet comprising macitentan”. The milestone feed surfaced a patent-application signal described as “The tablet comprising macitentan”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO